Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) presented new data yesterday on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference. The presentation, titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies," was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference's opening day.
The presentation highlighted CEACAM6 as a highly attractive therapeutic target based on its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies. This VHH demonstrated preferential binding to tumor-expressed CEACAM6, supporting the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects.
This work builds on the clinical foundation set by Tumor Defense Breaker™, L-DOS47, Helix's lead CEACAM6-targeted candidate, which has shown favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC). According to the company, the presentation generated strong interest and discussion among conference participants, reflecting the growing recognition of CEACAM6 as an important emerging target in oncology.
A copy of Dr. Davis' presentation is available on the Company's website at this link.
World ADC London is a global, annual conference dedicated to the discovery, development, and commercialization of ADCs. Now in its 16th year, it brings together more than 700 industry stakeholders from over 240 companies. More information can be found at the conference website.
Helix BioPharma is an oncology company with a pipeline led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company also advances two pre-IND candidates: LEUMUNA™ and GEMCEDA™. For more information, visit Helix BioPharma's website.
